What is Canagliflozin (SGLT2 inhibitor) and how does it affect longevity?

Canagliflozin (SGLT2 inhibitor) is a pharmaceuticals-based intervention that research suggests may add 1.0 years to your lifespan compared to the average person. SGLT2 inhibitor that causes urinary glucose excretion and extended mouse lifespan by +14% in males in the NIA ITP — a sex-specific finding with a critical warning: the same drug may reduce lifespan in aged females at elevated blood concentrations. Our analysis of the scientific literature gives this intervention an overall evidence rating of "Limited" (60%), combining peer-reviewed research (weighted at 85%) with expert consensus (15%). This rating reflects both the quality and quantity of available evidence — meaning early evidence is suggestive but limited by small studies, lack of human trials, or inconsistent findings.

Is canagliflozin (sglt2 inhibitor) scientifically proven to extend lifespan?

Canagliflozin (SGLT2 inhibitor) has a scientific evidence score of 60% based on our analysis of peer-reviewed research. It's important to understand that no intervention has been "proven" to extend human lifespan in a definitive randomized controlled trial — such a study would require following thousands of people for decades. What we do have is a body of evidence from multiple research approaches: large observational cohort studies tracking health outcomes over 10-30+ years, randomized controlled trials measuring disease risk factors and biomarkers of aging, mechanistic studies explaining how the intervention affects cellular aging processes, and meta-analyses that combine results across multiple studies. Our scoring weights meta-analyses and large RCTs most heavily, followed by prospective cohort studies, then smaller trials and pre-clinical research. The lower science score reflects that much of the current evidence comes from preliminary studies, animal models, or small trials that need replication.

How many years can using canagliflozin (sglt2 inhibitor) add to my life?

Canagliflozin (SGLT2 inhibitor) has an overall evidence score of 60% (rated "Limited"), placing it among the less-established pharmaceuticals interventions we evaluate. With a potential impact of 1.0 years, the individual effect is smaller — but still meaningful as part of a comprehensive approach. Different interventions work through distinct biological mechanisms (metabolic pathways, inflammatory cascades, hormonal signaling, cellular repair), which means they often complement rather than compete with each other. Visit our Rankings page to compare all pharmaceuticals interventions side by side.

What are the risks or side effects of canagliflozin (sglt2 inhibitor)?

Pharmaceutical interventions carry meaningful risks including side effects, drug interactions, and potential long-term effects that aren't fully characterized for off-label longevity use. These should only be considered under medical supervision, ideally with a physician experienced in longevity medicine. Regular blood work monitoring is essential.

Can I combine canagliflozin (sglt2 inhibitor) with other longevity interventions?

Yes, and in fact most longevity researchers recommend combining multiple evidence-based interventions for the greatest overall effect. Pharmaceutical interventions should be approached cautiously when combining with supplements, as drug interactions are common. For example, metformin may reduce some exercise benefits; rapamycin affects immune function; and berberine interacts with many medications through CYP enzyme pathways. Always disclose all supplements and medications to your prescribing physician.

How long until I see results from using canagliflozin (sglt2 inhibitor)?

Pharmaceutical effects on biomarkers (blood glucose, inflammatory markers, mTOR activity) can appear within weeks. However, demonstrating actual lifespan extension in humans requires decades of data, which is why much of the evidence relies on surrogate endpoints and animal models. Monitor key biomarkers regularly to track your individual response. It's worth noting that the most important longevity benefits — reduced risk of chronic disease and increased healthspan — are largely invisible in day-to-day experience. You won't "feel" your cancer risk dropping or your telomeres lengthening. This is why tracking objective biomarkers (blood work, body composition, cardiovascular fitness tests) is valuable for maintaining motivation and confirming the intervention is working for you.

Canagliflozin (SGLT2 inhibitor)

Estimated longevity benefit: +1.0 years. Evidence score: 60/100.

Overview

SGLT2 inhibitor that causes urinary glucose excretion and extended mouse lifespan by +14% in males in the NIA ITP — a sex-specific finding with a critical warning: the same drug may reduce lifespan in aged females at elevated blood concentrations.

Evidence assessment

Canagliflozin belongs to the SGLT2 inhibitor class — drugs that block the sodium-glucose cotransporter-2 protein in kidney tubules, causing glucose to be excreted in the urine rather than reabsorbed into the bloodstream. Originally developed for type 2 diabetes, SGLT2 inhibitors (including empagliflozin, dapagliflozin) have demonstrated cardiovascular and renal benefits in landmark trials (EMPA-REG OUTCOME, CANVAS, CREDENCE) that were unexpected for diabetes drugs and point to mechanisms beyond glucose lowering.

The ITP Finding: Miller et al. (2020) in *JCI Insight* and Harrison et al. (2024) in *GeroScience*: - +14% median lifespan in males at 180 ppm, started at 7 months - +9% maximum lifespan in males — longevity benefit extends to the longest-lived animals - Late start (16 months): Still +13.8% in males — the effect holds even at older ages - Females: No benefit in young-start cohort - Critical finding: Aged females showed -6.1% lifespan REDUCTION in the late-start cohort - Blood levels of canagliflozin were 20-fold higher in aged females vs. aged males — suggesting age-sex-specific pharmacokinetics that may drive toxicity

The Sex-Specific Pharmacology Warning: This is the most important cautionary finding in the ITP's 20-year history: the same drug that extends male lifespan may reduce female lifespan. The mechanism likely involves dramatically higher blood concentrations in aged females — either from reduced clearance or altered distribution. This is not a minor statistical noise; it's a consistent finding that has major implications for any extrapolation to human use.

Mechanisms of Male Lifespan Extension: 1. Metabolic caloric restriction mimicry: Urinary glucose loss (~70g/day at clinical doses) forces a shift to fat oxidation, activating AMPK and partially mimicking caloric restriction 2. Ketone elevation: SGLT2 inhibition increases blood ketone levels (β-hydroxybutyrate), which has anti-inflammatory, histone deacetylase-inhibiting, and neuroprotective properties 3. Visceral fat reduction: Male mice on canagliflozin show reduced visceral adiposity — removing a primary driver of age-related inflammation 4. Cardiac load reduction: Urinary glucose excretion reduces osmotic and hemodynamic cardiac load, explaining the cardiac benefits seen in human trials 5. Reduced mTORC1 activity: Some evidence that SGLT2 inhibitors modulate mTOR signaling in a direction consistent with longevity benefits

Human Evidence: Multiple large cardiovascular outcome trials (CANVAS, EMPA-REG, CREDENCE, DAPA-HF) have shown SGLT2 inhibitors reduce cardiovascular death and hospitalization in diabetes patients. Whether this reflects a longevity effect or just cardiovascular protection is unclear. The EMPACT-MI and other trials are extending this to non-diabetic populations.

The Bottom Line on Sex: Any longevity consideration of canagliflozin must account for the female toxicity signal. The ITP finding is a warning, not a nuance — aged females had both higher drug exposure AND worse outcomes. This is a case study in why sex-stratified analysis matters.

Implementation protocol

Critical Warning: - Canagliflozin (Invokana) is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease — NOT for longevity - The ITP found canagliflozin may REDUCE lifespan in aged females — this is a critical sex-specific safety signal - Off-label longevity use requires physician supervision; especially caution in women - Contraindicated in: eGFR <30 ml/min/1.73m², end-stage renal disease, dialysis, type 1 diabetes (risk of DKA), recurrent urinary/genital infections

FDA-Approved Dosing (for approved indications): - Canagliflozin (Invokana): 100–300mg once daily - Other SGLT2 inhibitors: Empagliflozin (Jardiance) 10–25mg, Dapagliflozin (Farxiga) 5–10mg - SGLT2 inhibitors as a class have similar mechanisms — the ITP specifically tested canagliflozin

Monitoring: - eGFR and creatinine: Essential baseline and ongoing monitoring — these drugs depend on kidney function - HbA1c and fasting glucose: Metabolic benefit confirmation - Urinalysis: Increased glucose in urine predisposes to UTIs and fungal infections (especially in women) - Ketones: Euglycemic DKA is a rare but serious complication, especially in periods of fasting/surgery - Blood pressure: SGLT2 inhibitors have mild antihypertensive effects — may need medication adjustment

Human Cardiovascular Evidence: - CANVAS Trial: Canagliflozin reduced major cardiovascular events by 14% vs. placebo in type 2 diabetes - CREDENCE: Canagliflozin reduced kidney disease progression by 30% in CKD patients - These are meaningful benefits, but these populations are not the general longevity-seeking public

Sex-Specific Note: Given the ITP female toxicity signal, women without clear indications (diabetes, heart failure, CKD) should be especially cautious about off-label longevity use. The finding that aged female mice had 20-fold higher blood concentrations suggests pharmacokinetic differences that may also exist in older women.

Scientific citations

Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin (GeroScience · 2024)
Supports
Miller RA, Harrison DE, Cortopassi GA, et al.
Follow-up ITP study with late-start canagliflozin: confirms male lifespan benefit persists when treatment begins in later life. Provides additional pharmacokinetic data on the sex difference in drug exposure.
View paper
Canagliflozin extends lifespan in genetically heterogeneous male but not female mice (JCI Insight · 2020)
Supports
Miller RA, Harrison DE, Allison DB, et al.
ITP primary result: canagliflozin extended median lifespan +14% in males. Late-start cohort: +13.8% in males. Critical finding: aged females showed -6.1% lifespan reduction with 20-fold higher blood concentrations.
View paper
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Trial) (New England Journal of Medicine · 2017)
Supports
Neal B, Perkovic V, Mahaffey KW, et al.
CANVAS Trial: canagliflozin reduced major cardiovascular events by 14% and slowed renal progression in 10,142 type 2 diabetes patients. Human evidence for cardiovascular longevity benefit, though in diabetic population.
View paper
SGLT2 inhibitors and risk of adverse effects in older adults: a systematic review (JAMA Internal Medicine · 2020)
Questions
Heyward J, Mansour O, Olson L, et al.
SGLT2 inhibitors associated with increased risks of urinary tract infections, genital mycotic infections, and diabetic ketoacidosis in real-world populations. Sex-specific toxicity signal from ITP must be considered.
View paper

Expert perspectives

Brian Kennedy, PhD Supports: Canagliflozin's ITP result is interesting on two levels: it extends male lifespan through mechanisms that look like metabolic reprogramming, and the female toxicity finding is a warning that sex-stratified biology can flip from benefit to harm.
Peter Attia, MD Supports: The SGLT2 inhibitor class has the strongest cardiovascular outcome trial data of any diabetes drug class. For patients with heart failure or CKD, the longevity case is already established. The ITP adds an intriguing preclinical layer.
Peter Diamandis, MD Supports: SGLT2 inhibitors are one of the most exciting drug classes to emerge in the last decade. The longevity mechanisms — ketone elevation, caloric restriction mimicry, cardiac unloading — are exactly what longevity medicine is looking for.
Valter Longo, PhD Questions: You can achieve similar glucose-lowering without the UTI risks and potential sex-specific harms through time-restricted eating and reduced refined carbohydrate intake.
Luigi Ferrucci, MD, PhD Questions: The ITP female lifespan reduction finding is serious. We don't know if this translates to humans, but using canagliflozin off-label for longevity in women — especially older women — is not supportable by current evidence.